{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:35:47Z","timestamp":1793824547684,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abnormal levels of maternal biochemical markers used in multiple marker aneuploidy screening have been associated with adverse pregnancy outcomes. This study aims to assess if a combination of maternal characteristics and biochemical markers in the first and second trimesters can be used to screen for preeclampsia (PE). The secondary aim was to assess this combination in identifying pregnancies at risk for gestational hypertension and preterm birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case-control study used information on maternal characteristics and residual blood samples from pregnant women who have undergone multiple marker aneuploidy screening. The median multiple of the median (MoM) of first and second trimester biochemical markers in cases (women with PE, gestational hypertension and preterm birth) and controls were compared. Biochemical markers included pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PlGF), human chorionic gonadotropin (hCG), alpha feto-protein (AFP), unconjugated estriol (uE3) and Inhibin A. Logistic regression analysis was used to estimate screening performance using different marker combinations. Screening performance was defined as detection rate (DR) and false positive rate (FPR). Preterm and early-onset preeclampsia PE were defined as women with PE who delivered at\u2009&lt;\u200937 and\u2009&lt;\u200934\u00a0weeks of gestation, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 147 pregnancies with PE (81 term, 49 preterm and 17 early-onset), 295 with gestational hypertension, and 166 preterm birth. Compared to controls, PE cases had significantly lower median MoM of PAPP-A (0.77 vs 1.10,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), PlGF (0.76 vs 1.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and free-\u03b2 hCG (0.81 vs. 0.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the first trimester along with PAPP-A (0.82 vs 0.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and PlGF (0.75 vs 1.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in the second trimester. The lowest first trimester PAPP-A, PlGF and free \u03b2-hCG were seen in those with preterm and early-onset PE. At a 20% FPR, 67% of preterm and 76% of early-onset PE cases can be predicted using a combination of maternal characteristics with PAPP-A and PlGF in the first trimester. The corresponding DR was 58% for gestational hypertension and 36% for preterm birth cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maternal characteristics with first trimester PAPP-A and PlGF measured for aneuploidy screening provided reasonable accuracy in identifying women at risk of developing early onset PE, allowing triage of high-risk women for further investigation and risk-reducing therapy. This combination was less accurate in predicting women who have gestational hypertension or preterm birth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-022-04514-4","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T07:03:57Z","timestamp":1646723037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia"],"prefix":"10.1186","volume":"22","author":[{"given":"Tianhua","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Melanie","family":"Bedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evasha","family":"Rasasakaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Priston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Mak-Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S.","family":"Meschino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Cuckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Mei-Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"3","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/AOG.0000000000001051","volume":"126","author":"Committee Opinion No","year":"2015","unstructured":"Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy. Obstet Gynecol. 2015;126(3):e31\u20137.","journal-title":"Obstet Gynecol"},{"key":"4514_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12884-019-2434-0","volume":"19","author":"M\u00c1 S\u00e1nchez-Dur\u00e1n","year":"2019","unstructured":"S\u00e1nchez-Dur\u00e1n M\u00c1, Bernabeu Garc\u00eda A, Calero I, Ramis Fossas J, Illescac T, Aviles MT, et al. Clinical application of a contingent screening strategy for trisomies with cell-free DNA: A pilot study. BMC Pregnancy Childbirth. 2019;19:274.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"8","key":"4514_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.17772\/gp\/57863","volume":"86","author":"E Litwi\u0144ska","year":"2015","unstructured":"Litwi\u0144ska E, Litwi\u0144ska M, Oszukowski P, Szaflik K, Litwinski W, Korcz M, et al. Biochemical markers in screening for preeclampsia and intrauterine growth restriction. Ginekol Pol. 2015;86(8):611\u20135.","journal-title":"Ginekol Pol"},{"key":"4514_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejogrb.2014.07.018","volume":"181","author":"JL Cohen","year":"2014","unstructured":"Cohen JL, Smilen KE, Bianco AT, Moshier EL, Ferrara LA, Stone JL. Predictive value of combined serum biomarkers for adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;181:89\u201394.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"4514_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000353907","volume":"34","author":"R Akolekar","year":"2013","unstructured":"Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Erratum appears in Fetal Diagn Ther. 2013;34(1):43.","journal-title":"Erratum appears in Fetal Diagn Ther"},{"key":"4514_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/uog.14819","volume":"46","author":"F Park","year":"2015","unstructured":"Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: Impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46:419\u201323.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/uog.14811","volume":"45","author":"A Tsiakkas","year":"2015","unstructured":"Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:591\u20138.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR8","doi-asserted-by":"crossref","unstructured":"Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH. Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks\u2019 gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;50:807.","DOI":"10.1002\/uog.15818"},{"key":"4514_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/uog.15849","volume":"47","author":"A Wright","year":"2016","unstructured":"Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH. Maternal serum PAPP-A and free \u03b2-hCG at 12, 22 and 32 weeks\u2019 gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:762\u20137.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"Suppl 1","key":"4514_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.12802","volume":"145","author":"LC Poon","year":"2019","unstructured":"Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1\u201333 (Erratum in: Int J Gynaecol Obstet. 2019;146:390-391).","journal-title":"Int J Gynaecol Obstet"},{"key":"4514_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/pd.4397","volume":"34","author":"LC Poon","year":"2014","unstructured":"Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34:618\u201327.","journal-title":"Prenat Diagn"},{"key":"4514_CR12","doi-asserted-by":"publisher","first-page":"103.e1","DOI":"10.1016\/j.ajog.2015.08.034","volume":"214","author":"N O\u2019Gorman","year":"2016","unstructured":"O\u2019Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11\u201313 weeks gestation. Am J Obstet Gynecol. 2016;214:103.e1-103.e12.","journal-title":"Am J Obstet Gynecol"},{"key":"4514_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12884-016-1169-4","volume":"16","author":"E Keikkala","year":"2016","unstructured":"Keikkala E, Koskinen S, Vuorela P, Laivuori H, Romppanen J, Heinonen S, et al. First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study. BMC Pregnancy Childbirth. 2016;16:378.","journal-title":"BMC Pregnancy Childbirth"},{"key":"4514_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1471-0528.1998.tb09943.x","volume":"105","author":"H Cuckle","year":"1998","unstructured":"Cuckle H, Sehmi I, Jones R. Maternal serum inhibin A can predict pre-eclampsia. BJOG An Int J Obstet Gynaecol. 1998;105:1101\u20133.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"4514_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/uog.6212","volume":"32","author":"K Spencer","year":"2008","unstructured":"Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:622\u20136.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/uog.14870","volume":"46","author":"D Wright","year":"2015","unstructured":"Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;46:42\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/uog.20256","volume":"54","author":"M Barjaktarovic","year":"2019","unstructured":"Barjaktarovic M, Korevaar TIM, Jaddoe VWV, de Rijke YB, Peeters RP, Steegers EAP. Human chorionic gonadotropin and risk of pre-eclampsia: prospective population-based cohort study. Ultrasound Obstet Gynecol. 2019;54:477\u201383.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR18","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.19082\/6186","volume":"10","author":"F Broumand","year":"2018","unstructured":"Broumand F, Salari Lak S, Nemati F, Mazidi A. A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women. Electron Physician. 2018;10:6186\u201392.","journal-title":"Electron Physician"},{"issue":"4","key":"4514_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1744-4667.2012.00132.x","volume":"14","author":"N Lakhi","year":"2012","unstructured":"Lakhi N, Govind A, Moretti M, Jones J. Maternal serum analytes as markers of adverse obstetric outcome. Obstet Gynaecol. 2012;14(4):267\u201373.","journal-title":"Obstet Gynaecol"},{"key":"4514_CR20","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/1471-0528.13495","volume":"122","author":"LL Jelliffe-Pawlowski","year":"2015","unstructured":"Jelliffe-Pawlowski LL, Baer RJ, Blumenfeld YJ, et al. Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth. BJOG An Int J Obstet Gynaecol. 2015;122:1484\u201393.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"4514_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/uog.18816","volume":"50","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-clampsia. Ultrasound Obstet Gynecol. 2017;50:492\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4514_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3343\/alm.2018.38.2.95","volume":"38","author":"H Caillon","year":"2018","unstructured":"Caillon H, Tardif C, Dumontet E, Winer N, Masson D. Evaluation of sFlt-1\/PlGF ratio for predicting and improving clinical management of pre-eclampsia: Experience in a specialized perinatal care center. Ann Lab Med. 2018;38:95\u2013101.","journal-title":"Ann Lab Med"},{"key":"4514_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/1471-0528.12128","volume":"120","author":"L Myatt","year":"2013","unstructured":"Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG An Int J Obstet Gynaecol. 2013;120:1183\u201391.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"issue":"239","key":"4514_CR24","first-page":"e1","volume":"196","author":"LJ Vatten","year":"2007","unstructured":"Vatten LJ, Eskild A, Nilsen TIL, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196(239):e1-6.","journal-title":"Am J Obstet Gynecol"},{"key":"4514_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/14767050802034545","volume":"21","author":"O Erez","year":"2008","unstructured":"Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21:279\u201387.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"4514_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/jhh.2013.148","volume":"28","author":"J Xiao","year":"2014","unstructured":"Xiao J, Shen F, Xue Q, et al. Is ethnicity a risk factor for developing preeclampsia? An analysis of the prevalence of preeclampsia in China. J Hum Hypertens. 2014;28:694\u20138.","journal-title":"J Hum Hypertens"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-022-04514-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T07:05:04Z","timestamp":1646723104000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-022-04514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1186\/s12884-022-04514-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-492997\/v1","asserted-by":"object"}]},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Board of North York General Hospital has approved the study on May 17, 2017. The Informed consent was waived by NYGH\u2019s REB. The informed consent was waived because our study meets the requirements specified in Canada\u2019s Tri-council policy statements C, Article 12.3 (\n                      \n                      ) for following reasons:1) The study is retrospective in nature. It is impracticable to seek consent from each individual patient. At the time of the sample collection, we did not know if a pregnancy will have an adverse pregnancy outcome (therefore will be include in the study). As screening tests were ordered by thousands of physicians across the province of Ontario, Canada, we do not have direct contact with patients.2) This study cannot be carried out without using residual samples.3) Using residual serum samples without patient consent will not have an adverse effect on patients because all subjects in the study have been managed using current standard of care guidelines for detection, follow-up, confirmation and treatment.4). We have de-identified the study dataset and study samples to protect the privacy of individuals and safeguard residual blood samples. No patients will be contacted. Only aggregate data will be published.All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The reagent kits used in the study were provided by PerkinElmer free of charge. Professor Howard Cuckle is a consultant of PerkinElmer. Dr. Elad Mei-Dan is an Editorial Board Member of BMC Pregnancy & Childbirth. The rest of the authors declare to have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}